Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 11Delirium 3Central Nervous System Diseases 2Supratentorial Neoplasms 1Spinal Cord Neoplasms 1Pain 1Neuroinflammatory Diseases 1Neurofibromatoses 1Neurocognitive Disorders 1Neoplasms 1Meningioma 1Intracranial Aneurysm 1Hypoxia 1Hydrocephalus 1Headache 1Epilepsy 1Emergence Delirium 1Cerebrovascular Disorders 1Abdominal Neoplasms 1

Interventions

Temozolomide 1Sodium Chloride 1Saline Solution 1Radiotherapy 1Injections 1Ferrosoferric Oxide 1Dexmedetomidine 13-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypoxia × Dexmedetomidine × CNS × Clear all
NCT04266665 2026-03-25

Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome

Aristotle University Of Thessaloniki

Phase 4 Completed
56 enrolled
CNS

Neuroinflammatory Diseases, Hypoxia, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡